Calprotectin in rheumatic diseases: a review

Calprotectin also known as MRP8/14 or S100A8/A9 is a heterodimeric complex of two S100 calcium-binding proteins: myeloid-related protein 8 (MRP-8 or S100A8) and MRP-14 (or S100A9). At present, according to many authors, it is considered that calprotectin MRP8/14 is a potentially more sensitive biomarker of disease activity in rheumatoid disease than conventional inflammatory indices such as the erythrocyte sedimentation rate, C-reactive protein and others. A review of the literature on concentration of calprotectin in patients with some rheumatic diseases (rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still’s disease, systemic vasculitis, polymyalgia rheumatica, ankylosis spondylitis, systemic lupus erythematosus, and primary Sjögren’s syndrome) is presented.

[1]  J. Yagüe,et al.  Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity , 2016, Arthritis Research & Therapy.

[2]  J. Yagüe,et al.  Serum Calprotectin Versus Acute‐Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors , 2016, Arthritis care & research.

[3]  T. Pisitkun,et al.  Elevated expressions of myeloid-related proteins-8 and -14 are danger biomarkers for lupus nephritis , 2016, Lupus.

[4]  J. Yagüe,et al.  Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. , 2015, Rheumatology.

[5]  Chun Li,et al.  Serum calprotectin—a promising diagnostic marker for adult-onset Still’s disease , 2015, Clinical Rheumatology.

[6]  A. Iagnocco,et al.  Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis. , 2015, Rheumatology.

[7]  Elżbieta Krzesiek.  Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children. , 2015, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[8]  D. Foell,et al.  MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. , 2015, Annals of the rheumatic diseases.

[9]  P. Oktayoğlu,et al.  Elevated serum levels of calprotectin (MRP8/MRP14) in patients with Behçet's disease and its association with disease activity and quality of life , 2015, Scandinavian journal of clinical and laboratory investigation.

[10]  P. Oktayoğlu,et al.  Elevated Serum Levels of Calprotectin (Myeloid-Related Protein 8/14) in Patients With Ankylosing Spondylitis and Its Association With Disease Activity and Quality of Life , 2014, Journal of Investigative Medicine.

[11]  R. Jonsson,et al.  Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjögren’s syndrome , 2014, Scandinavian journal of rheumatology.

[12]  O. Nived,et al.  Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. , 2013, Rheumatology.

[13]  L. Wedderburn,et al.  A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. , 2013, Rheumatology.

[14]  E. Martı́n-Mola,et al.  Calprotectin in Rheumatoid Arthritis , 2013, Molecular Diagnosis & Therapy.

[15]  D. Foell,et al.  The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. , 2009, Arthritis and rheumatism.

[16]  W. Nacken,et al.  Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock , 2007, Nature Medicine.

[17]  J. Edmonds,et al.  Power Doppler ultrasound in musculoskeletal disease: a systematic review. , 2006, Seminars in arthritis and rheumatism.

[18]  D. Foell,et al.  Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease. , 2006, Journal of the American College of Cardiology.

[19]  J. Gran,et al.  A longitudinal study of calprotectin in patients with polymyalgia rheumatica or temporal arteritis: relation to disease activity , 2005, Scandinavian journal of rheumatology.

[20]  Marcin Szkudlarek,et al.  Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[21]  T. Uchida,et al.  Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. , 2002, Journal of proteome research.

[22]  T. Lyberg,et al.  Functional and clinical aspects of the myelomonocyte protein calprotectin. , 1997, Molecular pathology : MP.

[23]  R. Jonsson,et al.  Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. , 1994, The Journal of rheumatology.

[24]  G. Hughes,et al.  Calprotectin in Patients with Systemic Lupus Erythematosus: Relation to Clinical and Laboratory Parameters of Disease Activity , 1993, Lupus.

[25]  M. Fagerhol,et al.  The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. , 1991, Scandinavian journal of rheumatology.

[26]  I. Dale,et al.  A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. , 1980, Bulletin europeen de physiopathologie respiratoire.